PRMT5 and neoplasm: The type 1 PRMT inhibitor, GSK3368715 was analyzed in 249 cancer cell lines representing 12 different tumors and was shown to have significant tumor‐suppressive activity, that synergizes on the addition of a PRMT5 inhibitor (GSK3368715).